iShares U.S. Oil & Gas Exploration & Production ETF (IEO)
- Previous Close
108.88 - Open
108.07 - Bid 106.61 x 1800
- Ask 110.36 x 1200
- Day's Range
107.46 - 108.75 - 52 Week Range
78.70 - 112.72 - Volume
180,479 - Avg. Volume
160,949 - Net Assets 770.07M
- NAV 108.48
- PE Ratio (TTM) 7.16
- Yield 2.44%
- YTD Daily Total Return 17.03%
- Beta (5Y Monthly) 0.65
- Expense Ratio (net) 0.40%
The fund will invest at least 80% of its assets in the component securities of the index and in investments that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, as well as in securities not included in the index, but which BFA believes will help the fund track the index. The fund is non-diversified.
iShares
Fund Family
Equity Energy
Fund Category
770.07M
Net Assets
2006-05-01
Inception Date
Performance Overview: IEO
Trailing returns as of 4/26/2024. Category is Equity Energy.
People Also Watch
Holdings: IEO
Top 10 Holdings (70.73% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: IEO
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetMOS: What does Argus have to say about MOS?
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetAnalyst Report: ASML Holding N.V.
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice TargetMOS: Raising target price to $34.00
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target